Voltar
Carta Acesso aberto Revisado por pares
BIBTEX RIS

Evaluation of diagnostic procedures

2002; BMJ; Volume: 324; Issue: 7350 Linguagem: Inglês

10.1136/bmj.324.7350.1391

ISSN

0959-8138

Autores

Victor F. Froelicher,

Resumo

vival data can be postponed to the postmarketing period.In particular, all the parties concerned, including patients, should agree on the assessment criteria before clinical trials are started.These measures should shorten the time to introduce cancer drugs that might make a difference to patients.The view of the author does not necessarily reflect the view of the MEB of the Netherlands.

Referência(s)